IntraOp Announces First Randomized Phase II Selection Trial of FLASH Versus Conventional Radiotherapy for Patients with Localized Carcinomas

SUNNYVALE, Calif.–(BUSINESS WIRE)–IntraOp Medical Corporation announced the world’s first Phase II Electron FLASH Trial. It marks the first time a randomized trial will compare FLASH radiotherapy* to conventional radiotherapy in treating nonmelanoma skin cancer (NMSC). It is the second clinical human trial to use the IntraOp® Mobetron® electron-based linear accelerator…


ADVERTISEMENT — Advertise With Biotech Networks